Insurance and Real Estate Committee
JOINT FAVORABLE REPORT
Bill No.: HB-6587
AN ACT CONCERNING HEALTH INSURANCE COVERAGE FOR
Title: EPINEPHRINE CARTRIDGE INJECTORS.
Vote Date: 3/22/2021
Vote Action: Joint Favorable Substitute
PH Date: 3/9/2021
File No.:
Disclaimer: The following JOINT FAVORABLE Report is prepared for the benefit of the
members of the General Assembly, solely for purposes of information, summarization and
explanation and does not represent the intent of the General Assembly or either chamber
thereof for any purpose.
SPONSORS OF BILL:
Insurance and Real Estate Committee
REASONS FOR BILL:
Many families are forced to pay high, out-of-pocket costs for epinephrine cartridge injectors
because they are not covered by insurance. This bill provides that certain individual and
group health insurance policies shall not impose a coinsurance, copayment, deductible or
out-of-pocket expense for a covered epinephrine cartridge injector in an amount that is
greater than twenty-five dollars.
SUBSTITUTE LANGUAGE:
Language was changed to reflect the start date of the law as January 1, 2022
RESPONSE FROM ADMINISTRATION/AGENCY:
None Expressed
NATURE AND SOURCES OF SUPPORT:
Patricia Donovan, Connecticut Resident: Ms. Donovan testified that the cost of
epinephrine cartridge injectors is increasing and oftentimes insurance does not provide
coverage. Connecticut ranks fifth highest among states for food allergy diagnoses and
anaphylaxis events. 10% of children and adults are food allergic and need epinephrine.
NATURE AND SOURCES OF OPPOSITION:
Connecticut Association of Health Plans: CAHP testified that the bill as written does not
affect the price of epinephrine injectors, but rather shifts the burden of cost from out-of-pocket
costs to premium costs. This will incentivize cost increases from pharmaceutical companies
because consumers are mostly protected from the impact.
Reported by: Mallory Ferrick Date: April 1, 2021
Page 2 of 2 HB-6587


Statutes affected:
File No. 793: